BACKGROUND: The whole Plasmodium falciparum sporozoite (PfSPZ) vaccine is being evaluated for malaria prevention. The vaccine is administered intravenously for maximal efficacy. Direct venous inoculation (DVI) with PfSPZ vaccine has been safe, tolerable, and feasible in adults, but safety data for children and infants are limited. METHODS: We conducted an age de-escalation, dose-escalation randomized controlled trial in Siaya County, western Kenya. Children and infants (aged 5-9 years, 13-59 months, and 5-12 months) were enrolled into 13 age-dose cohorts of 12 participants and randomized 2:1 to vaccine or normal saline placebo in escalating doses: 1.35 × 105, 2.7 × 105, 4.5 × 105, 9.0 × 105, and 1.8 × 106 PfSPZ, with the 2 highest doses given twice, 8 weeks apart. Solicited adverse events (AEs) were monitored for 8 days after vaccination, unsolicited AEs for 29 days, and serious AEs throughout the study. Blood taken prevaccination and 1 week postvaccination was tested for immunoglobulin G antibodies to P. falciparum circumsporozoite protein (PfCSP) using enzyme-linked immunosorbent assay. RESULTS:Rates of AEs were similar in vaccinees and controls for solicited (35.7% vs 41.5%) and unsolicited (83.9% vs 92.5%) AEs, respectively. No related grade 3 AEs, serious AEs, or grade 3 laboratory abnormalities occurred. Most (79.0%) vaccinations were administered by a single DVI. Among those in the 9.0 × 105 and 1.8 × 106 PfSPZ groups, 36 of 45 (80.0%) vaccinees and 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001). CONCLUSIONS:PfSPZ vaccine in doses as high as 1.8 × 106 can be administered to infants and children by DVI, and was safe, well tolerated, and immunogenic. CLINICAL TRIALS REGISTRATION: NCT02687373. Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: The whole Plasmodium falciparum sporozoite (PfSPZ) vaccine is being evaluated for malaria prevention. The vaccine is administered intravenously for maximal efficacy. Direct venous inoculation (DVI) with PfSPZ vaccine has been safe, tolerable, and feasible in adults, but safety data for children and infants are limited. METHODS: We conducted an age de-escalation, dose-escalation randomized controlled trial in Siaya County, western Kenya. Children and infants (aged 5-9 years, 13-59 months, and 5-12 months) were enrolled into 13 age-dose cohorts of 12 participants and randomized 2:1 to vaccine or normal saline placebo in escalating doses: 1.35 × 105, 2.7 × 105, 4.5 × 105, 9.0 × 105, and 1.8 × 106 PfSPZ, with the 2 highest doses given twice, 8 weeks apart. Solicited adverse events (AEs) were monitored for 8 days after vaccination, unsolicited AEs for 29 days, and serious AEs throughout the study. Blood taken prevaccination and 1 week postvaccination was tested for immunoglobulin G antibodies to P. falciparum circumsporozoite protein (PfCSP) using enzyme-linked immunosorbent assay. RESULTS: Rates of AEs were similar in vaccinees and controls for solicited (35.7% vs 41.5%) and unsolicited (83.9% vs 92.5%) AEs, respectively. No related grade 3 AEs, serious AEs, or grade 3 laboratory abnormalities occurred. Most (79.0%) vaccinations were administered by a single DVI. Among those in the 9.0 × 105 and 1.8 × 106 PfSPZ groups, 36 of 45 (80.0%) vaccinees and 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001). CONCLUSIONS: PfSPZ vaccine in doses as high as 1.8 × 106 can be administered to infants and children by DVI, and was safe, well tolerated, and immunogenic. CLINICAL TRIALS REGISTRATION: NCT02687373. Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Judith E Epstein; Kristopher M Paolino; Thomas L Richie; Martha Sedegah; Alexandra Singer; Adam J Ruben; Sumana Chakravarty; April Stafford; Richard C Ruck; Abraham G Eappen; Tao Li; Peter F Billingsley; Anita Manoj; Joana C Silva; Kara Moser; Robin Nielsen; Donna Tosh; Susan Cicatelli; Harini Ganeshan; Jessica Case; Debbie Padilla; Silas Davidson; Lindsey Garver; Elizabeth Saverino; Tooba Murshedkar; Anusha Gunasekera; Patrick S Twomey; Sharina Reyes; James E Moon; Eric R James; Natasha Kc; Minglin Li; Esteban Abot; Arnel Belmonte; Kevin Hauns; Maria Belmonte; Jun Huang; Carlos Vasquez; Shon Remich; Mary Carrington; Yonas Abebe; Amy Tillman; Bradley Hickey; Jason Regules; Eileen Villasante; B Kim Lee Sim; Stephen L Hoffman Journal: JCI Insight Date: 2017-01-12
Authors: Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy Journal: Lancet Infect Dis Date: 2017-02-16 Impact factor: 25.071
Authors: Andrew S Ishizuka; Kirsten E Lyke; Adam DeZure; Andrea A Berry; Thomas L Richie; Floreliz H Mendoza; Mary E Enama; Ingelise J Gordon; Lee-Jah Chang; Uzma N Sarwar; Kathryn L Zephir; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Sumana Chakravarty; Anita Manoj; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha K C; Tooba Murshedkar; Hope DeCederfelt; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Matthew B Laurens; Christopher V Plowe; Barbara Flynn; William R Whalen; J P Todd; Jay Noor; Srinivas Rao; Kailan Sierra-Davidson; Geoffrey M Lynn; Judith E Epstein; Margaret A Kemp; Gary A Fahle; Sebastian A Mikolajczak; Matthew Fishbaugher; Brandon K Sack; Stefan H I Kappe; Silas A Davidson; Lindsey S Garver; Niklas K Björkström; Martha C Nason; Barney S Graham; Mario Roederer; B Kim Lee Sim; Stephen L Hoffman; Julie E Ledgerwood; Robert A Seder Journal: Nat Med Date: 2016-05-09 Impact factor: 53.440
Authors: Prasad Ravi; Ravi Ashwath; James Strainic; Hong Li; Jon Steinberg; Christopher Snyder Journal: Congenit Heart Dis Date: 2015-08-24 Impact factor: 2.007
Authors: Ally Olotu; Vicente Urbano; Ali Hamad; Martin Eka; Mwajuma Chemba; Elizabeth Nyakarungu; Jose Raso; Esther Eburi; Dolores O Mandumbi; Dianna Hergott; Carl D Maas; Mitoha O Ayekaba; Diosdado N Milang; Matilde R Rivas; Tobias Schindler; Oscar M Embon; Adam J Ruben; Elizabeth Saverino; Yonas Abebe; Natasha Kc; Eric R James; Tooba Murshedkar; Anita Manoj; Sumana Chakravarty; Minglin Li; Matthew Adams; Christopher Schwabe; J Luis Segura; Claudia Daubenberger; Marcel Tanner; Thomas L Richie; Peter F Billingsley; B Kim Lee Sim; Salim Abdulla; Stephen L Hoffman Journal: Am J Trop Med Hyg Date: 2018-01-01 Impact factor: 2.345
Authors: Said A Jongo; L W Preston Church; Ali T Mtoro; Sumana Chakravarty; Adam J Ruben; Phillip A Swanson; Kamaka R Kassim; Maximillian Mpina; Anneth-Mwasi Tumbo; Florence A Milando; Munira Qassim; Omar A Juma; Bakari M Bakari; Beatus Simon; Eric R James; Yonas Abebe; Natasha Kc; Elizabeth Saverino; Linda Gondwe; Fabian Studer; Martina Fink; Glenda Cosi; Jill El-Khorazaty; David Styers; Robert A Seder; Tobias Schindler; Peter F Billingsley; Claudia Daubenberger; B Kim Lee Sim; Marcel Tanner; Thomas L Richie; Salim Abdulla; Stephen L Hoffman Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345
Authors: M Oneko; Y R Cherop; T Sang; J R Gutman; R Wiegand; E M Nyang'au; A D Odila; D Akach; M J Hamel; A M Samuels; S Kariuki; Y Abebe; E L Nzuu; W Wijayalath; E R James; B K L Sim; P F Billingsley; T L Richie; S L Hoffman; R A Seder; L C Steinhardt Journal: Vaccine Date: 2020-05-19 Impact factor: 3.641
Authors: Martina Oneko; Laura C Steinhardt; Reuben Yego; Ryan E Wiegand; Phillip A Swanson; Natasha Kc; Dorcas Akach; Tony Sang; Julie R Gutman; Elizabeth L Nzuu; Allan Dungani; B Kim Lee Sim; Paul Ndaya Oloo; Kephas Otieno; Dennis K Bii; Peter F Billingsley; Eric R James; Simon Kariuki; Aaron M Samuels; Said Jongo; Winnie Chebore; Salim Abdulla; Claudia Daubenberger; Maxmillian Mpina; David Styers; Gail E Potter; Ginnie Abarbanell; Thomas L Richie; Stephen L Hoffman; Robert A Seder Journal: Nat Med Date: 2021-09-13 Impact factor: 53.440
Authors: Said Abdallah Jongo; L W Preston Church; Vicente Urbano Nsue Ndong Nchama; Ali Hamad; Raul Chuquiyauri; Kamaka Ramadhani Kassim; Thabit Athuman; Anna Deal; K C Natasha; Ali Mtoro; Maxmillian Mpina; Elizabeth Nyakarungu; Gertrudis Owono Bidjimi; Marta Alene Owono; Escolastica Raquel Mansogo Maye; Martin Eka Ondo Mangue; Genaro Nsue Nguema Okomo; Beltran Ekua Ntutumu Pasialo; Dolores Mbang Ondó Mandumbi; María-Silvia A López Mikue; Fortunata Lobede Mochomuemue; Mariano Obiang Obono; Juan Carlos Momo Besaha; José Raso Bijeri; Gabriel Mba Abegue; Yolanda Rimoy Veri; Ines Toichoa Bela; Federico Comsil Chochi; José Enrique Lima Sánchez; Vanessa Pencelli; Griselda Gayozo; Jose Antonio Esono Mba Nlang; Tobias Schindler; Eric R James; Yonas Abebe; Laurence Lemiale; Thomas C Stabler; Tooba Murshedkar; Mei-Chun Chen; Christopher Schwabe; Josea Ratsirarson; Matilde Riloha Rivas; Mitoha Ondo'o Ayekaba; Diosdado Vicente Nsue Milang; Carlos Cortes Falla; Wonder P Phiri; Guillermo A García; Carl D Maas; Bonifacio Manguire Nlavo; Marcel Tanner; Peter F Billingsley; B Kim Lee Sim; Claudia Daubenberger; Stephen L Hoffman; Salim Abdulla; Thomas L Richie Journal: Am J Trop Med Hyg Date: 2022-02-07 Impact factor: 2.345
Authors: Stephen L Hoffman; Peter G Kremsner; Benjamin Mordmüller; Zita Sulyok; Mihály Sulyok; Zsofia Molnar; Albert Lalremruata; Carlos Lamsfus Calle; Patricia Granados Bayon; Meral Esen; Markus Gmeiner; Jana Held; Henri-Lynn Heimann; Tamirat Gebru Woldearegai; Javier Ibáñez; Judith Flügge; Rolf Fendel; Andrea Kreidenweiss; Natasha Kc; Tooba Murshedkar; Sumana Chakravarty; Pouria Riyahi; Peter F Billingsley; L W Preston Church; Thomas L Richie; B Kim Lee Sim Journal: NPJ Vaccines Date: 2022-08-23 Impact factor: 9.399